BioSig Technologies Signs a New Licensing Agreement with Mayo Clinic
September 12 2019 - 7:52AM
BioSig Technologies, Inc. (NASDAQ: BSGM), a medical
technology company developing a proprietary biomedical signal
processing platform designed to address an unmet technology need
for the electrophysiology (EP) marketplace, today announced that it
signed a new licensing agreement with Mayo Clinic.
The new agreement aims to develop a new product pipeline to
support some of the more advanced features of BioSig’s first
product, PURE EP™ System. The development program will be run under
the leadership of Samuel J. Asirvatham, M.D., Mayo Clinic’s
Vice-Chair of Innovation and Medical Director, Electrophysiology
Laboratory.
“We are very pleased to expand our relationship with the
outstanding physician team at Mayo Clinic. Their commitment to
improving patient care resonates deeply with our Company’s mission
to bring innovative technological solutions to medicine, and we are
looking forward to this next chapter in our collaboration. The new
product that we intend to develop under the latest licensing
will seek to significantly advance the current arrhythmia
treatments. It will be an exciting journey, and we look forward to
reporting on our progress,” commented Kenneth L. Londoner, Chairman
and CEO of BioSig Technologies, Inc.
BioSig was recently added to the Russell 3000 Index and allowed
33 patent claims covering its PURE EP™ System. In the first half of
2019 BioSig successfully conducted first patient cases using its
PURE EP™ System at the Texas Cardiac Arrhythmia Institute in
Austin, TX, Greenville Memorial Hospital in Greenville, SC and
Indiana University School of Medicine. The Company signed a 10-year
collaboration agreement with Mayo Clinic in March 2017.
About BioSig TechnologiesBioSig Technologies is
a medical technology company developing a proprietary biomedical
signal processing platform designed to improve the
electrophysiology (EP) marketplace (www.biosig.com). Led by a
proven management team and a veteran Board of Directors, BioSig
Technologies is preparing to commercialize its PURE EP™ System. The
technology has been developed to address an unmet need in a large
and growing market.The Company’s first product, PURE EP™ System is
a computerized system intended for acquiring, digitizing,
amplifying, filtering, measuring and calculating, displaying,
recording and storing of electrocardiographic and intracardiac
signals for patients undergoing electrophysiology (EP) procedures
in an EP laboratory. The system is indicated for use under the
supervision of licensed healthcare practitioners who are
responsible for interpreting the data. This novel cardiac signal
acquisition and display system is engineered to assist
electrophysiologists in clinical decision-making during
electrophysiology procedures in patients with abnormal heart rates
and rhythms. BioSig’s ultimate goal is to deliver technology to
improve upon catheter ablation treatments for the prevalent and
potentially deadly arrhythmias, Atrial Fibrillation and Ventricular
Tachycardia. BioSig has partnered with Minnetronix on technology
development and received FDA 510(k) clearance for the PURE EP™
System in August 2018.
Forward-looking Statements This press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward- looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) our inability to manufacture our products and
product candidates on a commercial scale on our own, or in
collaboration with third parties; (ii) difficulties in obtaining
financing on commercially reasonable terms; (iii) changes in the
size and nature of our competition; (iv) loss of one or more key
executives or scientists; and (v) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
Natasha Drapeau
BioSig Technologies, Inc.
Executive Vice President
54 Wilton Road, 2nd floor
Westport, CT 06880
ndrapeau@biosigtech.com
203-409-5444, x119
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2023 to Apr 2024